Three years after shutting down development of its first cancer drug, gene-silencing startup Dicerna Therapeutics is charging forward with its plans to develop drugs for liver disease. Dicerna pivoted its attention to drugs that target the liver after stopping development of its tumor-fighting drug when it reported underwhelming results in two early-stage clinical trials in 2016.

Boston Biz Journal